Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235701 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
A Phase 1 study of Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT02235701 is a Phase 1 study of Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma that has completed, run by ImmunityBio. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02235701, a Phase 1 study of Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.
Conditions Studied
Interventions
- DRUG 250 mg/m2 aldoxorubicin
- DRUG 170 mg/m2 aldoxorubicin
Study Locations (1)
California
- Sarcoma Oncology Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-09-02 |
| Est. Completion | 2018-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02235701
The ClinicalTrials.gov registry entry for NCT02235701 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which 250 mg/m2 aldoxorubicin is the first listed.
NCT02235701 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02235701 about?
NCT02235701 is a clinical study titled "Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma". This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.
What is the current status of trial NCT02235701?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2014-09-02. Estimated completion is 2018-05-01.
What conditions does trial NCT02235701 study?
This clinical trial studies the following conditions: Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma.
What interventions are being tested in trial NCT02235701?
The interventions under investigation include: 250 mg/m2 aldoxorubicin (DRUG), 170 mg/m2 aldoxorubicin (DRUG).
Who is sponsoring clinical trial NCT02235701?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02235701 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.